6CM
GALT icon

683 Capital Management’s Galectin Therapeutics GALT Stock Holding History

683 Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-162,484
Closed -$453K – 186
2026
Q1 		$453K Hold
162,484
– – 0.02% 189
2025
Q4 		$676K Buy
+162,484
New +$856K 0.03% 173
2024
Q1 		– Sell
-111,035
Closed -$184K – 179
2023
Q4 		$184K Buy
+111,035
New +$215K 0.02% 209

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

683 Capital Management's GALT Position: Q2 2026 in Review

683 Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 162,484 shares — an estimated $453K sold.

683 Capital Management first reported a position in GALT in Q4 2023 and held it in 3 quarters. The position peaked at $676K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • 683 Capital Management reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 162,484 Galectin Therapeutics shares in Q2 2026, an estimated $453K.
  • 683 Capital Management first reported a position in Galectin Therapeutics in Q4 2023 and held it in 3 quarters.
  • 683 Capital Management's Galectin Therapeutics position peaked at $676K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.